England's National Health Service will soon offer nivolumab as a quick injection for cancer patients. This new method cuts ...

Participants received 480 mg of nivolumab and 160 mg of relatlimab intravenously once every 4 weeks for two cycles before ...

University of Southern California researchers have found a way to rebrand this oft-embarrassing sore subject by genetically ...

Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87 ...

The UK's National Health Service has introduced a quick injection method for administering the cancer drug Nivolumab, significantly reducing treatment time and hospital stays.

The herpes simplex virus type 1 (HSV-1), which affects almost two‑thirds of the world's population and is generally ...

A cancer-killing virus could soon be approved for use after shrinking tumours in a third of people with late-stage melanoma ...

Recent ASCO 2025 findings reveal new insights into melanoma treatment, highlighting challenges and advancements in adjuvant ...

A genetically modified herpes simplex virus, called RP1, has now been shown to destroy advanced melanoma tumors, even when ...

Gynecological clear cell cancers (CCCs), very aggressive forms of ovarian and endometrial malignancies, respond poorly to chemotherapy.  The low respo | Cancer ...

The complete remission of a testicular cancer patient receiving Mink Therapeutics Inc.’s allogeneic, off-the-shelf invariant natural killer T-cell therapy Agent-797 with nivolumab drove the company’s ...